Myelodysplastic syndromes — Rapid

Synopsis

Recognise persistent unexplained cytopenia, prove a clonal myeloid disorder, distinguish reversible mimics, stratify progression risk and combine supportive, disease-modifying and transplant care.

Suspect MDS with persistent unexplained macrocytic anaemia, bi- or pancytopenia, hypogranular neutrophils, pseudo-Pelger-Huët cells, abnormal platelets or circulating blasts.
First-line assessment excludes B12, folate, iron and copper deficiency, alcohol, medicines, renal, liver, thyroid, infection, autoimmune and splenic causes before marrow interpretation.
Confirm with marrow aspirate and trephine for morphology, cellularity, fibrosis and blasts plus cytogenetics and a myeloid molecular panel; one dysplastic-looking film is insufficient.
Use WHO or ICC subtype with IPSS-R or IPSS-M risk, performance, frailty, transfusion burden and patient goals rather than blast percentage alone.
Lower-risk care aims to improve cytopenia and quality of life using individualised transfusion, erythropoiesis-stimulating treatment in selected low-EPO anaemia and subtype-directed options.
Higher-risk disease requires early transplant assessment; azacitidine is a standard disease-modifying option for eligible adults not immediately receiving curative allogeneic transplantation.
Azacitidine is commonly 75 mg/m² subcutaneously or intravenously daily on days 1 to 7 every 28 days; assess response only after sufficient cycles unless progression or unacceptable toxicity occurs.
Allogeneic stem-cell transplantation is the only established curative treatment but eligibility depends on biological risk, comorbidity, donor, fitness and informed preference.

Key red flags

Fever, rigors, hypotension or confusion with neutropenia is a medical emergency requiring immediate empiric intravenous antibiotics.

Active bleeding with severe thrombocytopenia or coagulopathy requires urgent transfusion-laboratory and haematology coordination rather than waiting for routine marrow review.

New circulating blasts, rapid count deterioration, bone pain or rising LDH may represent AML transformation and requires urgent marrow and molecular classification.

Transformation pattern

Rapid worsening cytopenia, new blasts, fever, bone pain or tissue disease suggests AML evolution and accelerates classification.

Investigation priorities

First-line reversible-cause screenFirst stepFirst line

Prevent nutrient, medicine, infection or organ disease being mislabelled as a clonal neoplasm.

Management branches

Persistent unexplained cytopeniaExclude mimics then examine marrow

One or more blood counts remain low without a clear transient cause.

Repeat FBC, reticulocytes and film and assess nutrition, medicines, alcohol, organs, infection, autoimmune disease and spleen.
Perform marrow aspirate and trephine with morphology, flow, cytogenetics and molecular testing when cytopenia remains unexplained.
Integrate subtype and risk and identify germline clues before counselling or donor testing.

Key medicines

AzacitidineGive 75 mg/m² subcutaneously once daily on days 1 to 7, followed by 21 treatment-free days in each 28-day cycle; continue for at least 6 cycles and thereafter while benefit persists or until disease progression.Premedicate for nausea, monitor FBC, creatinine, bicarbonate and liver tests before each cycle and apply SmPC count and renal delay or reduction rules. Do not interchange this injection schedule with oral azacitidine; avoid pregnancy and breastfeeding and discuss fertility.

Epoetin alfaA common lower-risk MDS starting regimen is 30,000 international units subcutaneously once weekly, escalating to 60,000 units weekly if protocol response is inadequate after 8 weeks; stop if no meaningful erythroid response after the defined trial.Correct iron, B12 and folate deficiency, monitor haemoglobin and blood pressure and avoid haemoglobin overshoot. Review thrombosis risk and do not persist when response criteria are not met.

Open full textbook →Answer 2 questions